Clinical trials in Oldenburg In Holstein – page 61

840 clinical trials in Oldenburg In Holstein, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Oldenburg In Holstein at a glance

840

clinical trials

Research sites1

Quick filters

840 trials in Oldenburg In Holstein

Open in trial search

Acute lymphocytic leukaemia

Not recruiting

Study on Improving Treatment for Children and Adolescents with Acute Lymphoblastic Leukemia Using Bortezomib, Blinatumomab, and a Drug Combination

Registered drugNo placebo

Study on Improving Treatment for Children and Adolescents with Acute Lymphoblastic Leukemia Using Bortezomib, Blinatumomab, and a Drug Combination

Registered drugNo placebo

Germany

Participants:0–17 years
Substances:Blinatumomab
Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Contact Research Centre

Plasma cell myeloma+13

Not recruiting

Study on Atezolizumab and Drug Combinations for Advanced Malignancies in Patients from Previous Atezolizumab Trials

Registered drugNo placebo

Study on Atezolizumab and Drug Combinations for Advanced Malignancies in Patients from Previous Atezolizumab Trials

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Alectinib
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Malignant melanoma stage III

Not recruiting

Study on Pembrolizumab for Patients with High-Risk Stage III Melanoma After Surgery

Registered drug

Study on Pembrolizumab for Patients with High-Risk Stage III Melanoma After Surgery

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Deafness neurosensory

Not recruiting

Study on the Effectiveness and Safety of AC102 Injection vs. Oral Prednisolone for Patients with Sudden Hearing Loss

Registered drug

Study on the Effectiveness and Safety of AC102 Injection vs. Oral Prednisolone for Patients with Sudden Hearing Loss

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Prednisolone
Sponsor:AudioCure Pharma GmbH

Contact Research Centre

Breast cancer

Not recruiting

Study on Alpelisib and Fulvestrant for Men and Postmenopausal Women with Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA Mutation

Registered drug

Study on Alpelisib and Fulvestrant for Men and Postmenopausal Women with Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA Mutation

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Alpelisib
Sponsor:Novartis Pharma AG

Contact Research Centre

HER2 mutant non-small cell lung cancer

Not recruiting

Study on Trastuzumab Deruxtecan for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo

Study on Trastuzumab Deruxtecan for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:AstraZeneca AB

Contact Research Centre

Primary biliary cholangitis

Not recruiting

Study on the Long-Term Safety of Seladelpar for Patients with Primary Biliary Cholangitis

InvestigationalNo placebo

Study on the Long-Term Safety of Seladelpar for Patients with Primary Biliary Cholangitis

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Seladelpar
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Endometrial cancer stage III+1

Not recruiting

Study on Dostarlimab, Carboplatin, and Paclitaxel for Patients with Recurrent or Advanced Endometrial Cancer

Registered drug

Study on Dostarlimab, Carboplatin, and Paclitaxel for Patients with Recurrent or Advanced Endometrial Cancer

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Dostarlimab
Sponsor:Tesaro Inc.

Contact Research Centre

Diffuse large B-cell lymphoma+2

Not recruiting

Study on Golcadomide and R-CHOP Drug Combination for Patients with Untreated High-risk Large B-cell Lymphoma

Registered drug

Study on Golcadomide and R-CHOP Drug Combination for Patients with Untreated High-risk Large B-cell Lymphoma

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Apixaban
Sponsor:Celgene Corp.

Contact Research Centre

Breast cancer+1

Not recruiting

Study of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer

Registered drugNo placebo

Study of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:Novartis Pharma AG

Contact Research Centre

Psoriasis

Not recruiting

Study on Bimekizumab and Ustekinumab for Children and Teens with Moderate to Severe Plaque Psoriasis

Investigational

Study on Bimekizumab and Ustekinumab for Children and Teens with Moderate to Severe Plaque Psoriasis

Investigational

Germany

Participants:0–17 years
Substances:Bimekizumab
Sponsor:UCB Biopharma

Contact Research Centre

Hereditary angioedema with C1 esterase inhibitor deficiency

Not recruiting

Study on Deucrictibant and Icatibant for Treating Hereditary Angioedema Attacks in Adolescents and Adults

Registered drug

Study on Deucrictibant and Icatibant for Treating Hereditary Angioedema Attacks in Adolescents and Adults

Registered drug

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Deucrictibant
Sponsor:Pharvaris Netherlands B.V.

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Oldenburg In Holstein

What the registry says about research in the country

01 Metabolic Disorders

Innovative clinical trials focusing on Type 2 Diabetes management and treatments, including studies of novel weekly insulin alternatives and oral medications for glycemic control.

Glycemic Control Studies
Insulin Alternatives Research
Cardiovascular Outcomes

Multiple studies evaluating new therapeutic approaches for better diabetes management and reducing cardiovascular risks.

02 Weight Management

Comprehensive research into obesity treatment and weight-related conditions, examining new therapeutic combinations and their effects on weight loss and associated health conditions.

Weight Loss Interventions
Obesity Medications
Comorbidity Management

Studies focusing on innovative approaches to weight management and treating obesity-related health complications.

03 Cardiovascular Health

Research examining treatments for atherosclerotic cardiovascular disease and related conditions, with emphasis on preventing major adverse cardiovascular events.

Cardiovascular Risk Reduction
Lipid Management
Preventive Therapies

Trials evaluating new medications for improving cardiovascular outcomes in high-risk patients.

04 Gastrointestinal Studies

Clinical investigations of treatments for Crohn's Disease and other digestive conditions, focusing on long-term efficacy and safety of new therapeutic approaches.

Inflammatory Bowel Disease
Long-term Treatment Outcomes
Disease Management

Studies aimed at improving quality of life for patients with chronic gastrointestinal conditions.

05 Oncology Research

Advanced studies in colorectal cancer treatment and management, including innovative approaches to Stage II and III cancer therapy.

Cancer Treatment Protocols
Disease-Free Survival
Adjuvant Therapy

Trials evaluating new treatment strategies for improving outcomes in cancer patients.

Back to Germany All countries